Content about Health & Wellness

July 7, 2011

The Food and Drug Administration has approved an additional strength of a generic drug made by Lupin Pharmaceuticals for high blood pressure, Lupin said Wednesday.

BALTIMORE — The Food and Drug Administration has approved an additional strength of a generic drug made by Lupin Pharmaceuticals for high blood pressure, Lupin said Wednesday.

Lupin announced the approval of amlodipine besylate and benazepril hydrochloride capsules in the 5-mg/40-mg and 10-mg/40-mg strengths. The company already markets the drug in the 2.5-mg/10-mg, 5-mg/10-mg, 5-mg/20-mg and 10-mg/20-mg strengths.

July 7, 2011

The National Association of Chain Drug Stores has submitted comments to the Centers for Medicare and Medicaid Services regarding a proposed rule that would help to determine Medicaid beneficiary access to pharmacies and other healthcare providers.

ALEXANDRIA, Va. ­— The National Association of Chain Drug Stores has submitted comments to the Centers for Medicare and Medicaid Services regarding a proposed rule that would help to determine Medicaid beneficiary access to pharmacies and other healthcare providers.

NACDS urged CMS to ensure access to healthcare services for Medicaid beneficiaries that are comparable with the access that the general population has in a given geographic area, a requirement of the federal standard.

July 6, 2011

Pharmacy benefit manager Medco Health Solutions’ specialty pharmacy division, Accredo Health Group, has managed to drive down costs for treating hepatitis C by an average of $13,000 per patient, the company said Tuesday.

FRANKLIN LAKES, N.J. — Pharmacy benefit manager Medco Health Solutions’ specialty pharmacy division, Accredo Health Group, has managed to drive down costs for treating hepatitis C by an average of $13,000 per patient, the company said Tuesday.

Medco said Accredo had been successful in using genotype information to identify patients who only may need 24 weeks of therapy, as opposed to 48 weeks, thus reducing costs.

July 6, 2011

Discovery Communications recently announced the launch of a line of branded Discovery Fit & Health consumer products designed to provide proactive health and fitness lifestyle solutions for health-conscious consumers.

NEW YORK — Discovery Communications recently announced the launch of a line of branded Discovery Fit & Health consumer products designed to provide proactive health and fitness lifestyle solutions for health-conscious consumers.

July 6, 2011

A once-monthly formulation of a drug made by Amylin Pharmaceuticals, Eli Lilly and Alkermes improved glucose control in patients with Type 2 diabetes, according to results of a mid-stage clinical trial presented at the American Diabetes Association’s 71st Scientific Sessions.

SAN DIEGO — A once-monthly formulation of a drug made by Amylin Pharmaceuticals, Eli Lilly and Alkermes improved glucose control in patients with Type 2 diabetes, according to results of a mid-stage clinical trial presented at the American Diabetes Association’s 71st Scientific Sessions.

The three companies said once-monthly injections of the drug exenatide improved blood-sugar control and produced modest weight loss in the 121-patient phase-2 study.

July 6, 2011

Consuming nuts in place of carbohydrates may help improve long-term blood-sugar control and lower cholesterol levels among Type 2 diabetics, according to a new study.

FRESNO, Calif. — Consuming nuts in place of carbohydrates may help improve long-term blood-sugar control and lower cholesterol levels among Type 2 diabetics, according to a new study.

July 6, 2011

Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

SAN DIEGO — Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

MannKind said that patients taking the investigational inhaled insulin Afrezza (insulin human [rDNA origin]) with basal insulin came to view insulin therapy more positively during the 16-week study than those taking Eli Lilly’s injected Humalog (insulin lispro [rDNA origin]) with basal insulin.

July 6, 2011

People with lower percentages of body fat are not necessarily at lower risk for diabetes and heart disease, according to a new international study.

BOSTON — People with lower percentages of body fat are not necessarily at lower risk for diabetes and heart disease, according to a new international study.

The study identified a gene that is linked with having less body fat but also with having an increased risk of Type 2 diabetes and heart disease. The investigators examined the genomes of more than 75,000 people and found that the gene, IRS1, was linked to less body fat, but also to unhealthy levels of cholesterol and blood glucose.

July 6, 2011

Walgreens and Take Care Health Systems have entered into a relationship with Core Performance to offer Core Performance corporate wellness services to Take Care Health Systems employer clients and bolster its service portfolio.

DEERFIELD, Ill. — Walgreens and Take Care Health Systems have entered into a relationship with Core Performance to offer Core Performance corporate wellness services to Take Care Health Systems employer clients and bolster its service portfolio.

Take Care Health Systems is the nation's largest manager of employer health, pharmacy and fitness centers, with nearly 400 locations throughout the United States. As part of the agreement, Walgreens has made a minority investment in Core Performance.

July 5, 2011

APP Pharmaceuticals has received regulatory approval for the treatment of a complication related to hypothyroidism.

SCHAUMBURG, Ill. — APP Pharmaceuticals has received regulatory approval for the treatment of a complication related to hypothyroidism.

APP said that its levothyroxine sodium for injection will be marketed in single-dose 100-mcg, 200-mcg and 500-mcg vials. The drug is designed to treat myxedema coma, a life-threatening complication of hypothyroidism.

July 5, 2011

MediShield was selected as a winner of the 11th Annual New York Venture Summit Top Innovator award last month by YoungStartup Ventures. The award recognizes privately held companies from across the United States that play a leading role in innovation.

SAN DIEGO — MediShield was selected as a winner of the 11th Annual New York Venture Summit Top Innovator award last month by YoungStartup Ventures. The award recognizes privately held companies from across the United States that play a leading role in innovation.

MediShield was recognized for its CastShield line, which offers waterproof protection for casts, bandages, prosthetics and vascular compression products. CastShield is meeting a significant consumer demand, the company noted.

July 5, 2011

The dietary supplement industry last week took another legislative knock to the chin as it was associated with controversy surrounding mislabled conventional foods, specifically Lazy Cakes, a brownie that contains the dietary ingredient melatonin and purports to be a dietary supplement.

WASHINGTON — The dietary supplement industry last week took another legislative knock to the chin as it was associated with controversy surrounding mislabled conventional foods, specifically Lazy Cakes, a brownie that contains the dietary ingredient melatonin and purports to be a dietary supplement.

July 5, 2011

The Food and Drug Administration on Tuesday published long-awaited guidance on new dietary ingredients in the Federal Register.

WASHINGTON — The Food and Drug Administration on Tuesday published long-awaited guidance on new dietary ingredients in the Federal Register.

July 5, 2011

Hain Celestial expressed its continued commitment to a "back-to-basics approach to product labeling."

MELVILLE, N.Y. — Hain Celestial expressed its continued commitment to a "back-to-basics approach to product labeling."

July 5, 2011

The Food and Drug Administration has approved a drug made by Archimedes Pharma for treating breakthrough pain in cancer patients, Archimedes said last week.

BEDMINSTER, N.J. — The Food and Drug Administration has approved a drug made by Archimedes Pharma for treating breakthrough pain in cancer patients, Archimedes said last week.

Archimedes announced the approval of Lazanda (fentanyl) nasal spray for cancer patients who have acquired a tolerance to opioid drugs. Breakthrough pain is an intense, sudden pain that is unpredictable and often debilitating and occurs despite otherwise appropriate pain therapy.

July 5, 2011

The Food and Drug Administration has approved a drug made by Novartis for treating chronic obstructive pulmonary disease, the FDA said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Novartis for treating chronic obstructive pulmonary disease, the FDA said Friday.

The FDA approved Arcapta Neohaler (indacaterol inhalation powder) for long-term, once-daily maintenance of bronchodilator treatment of airflow obstruction in people with COPD, including chronic bronchitis and emphysema.

COPD, which often results from cigarette smoking, is the fourth-leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

July 5, 2011

Pfizer defended a drug used for smoking cessation Monday following reports of a Canadian study that found it raised the risk of heart problems.

NEW YORK — Pfizer defended a drug used for smoking cessation Monday following reports of a Canadian study that found it raised the risk of heart problems.

The 8,216-patient study of Chantix (varenicline), published in the Canadian Medical Association Journal, found that of the 4,908 patients who received Chantix, 52 had an increased risk of serious heart problems, with similar risks appearing in 27-of-the-3,308 patients who took placebo.

July 5, 2011

New graphic cigarette warning labels released last month by the Food and Drug Administration already appear to be having one desired effect: an increase in "quit smoking" queries to the national 1-800-QUIT-NOW smoking cessation line, the Associated Press reported Saturday.

ATLANTA — New graphic cigarette warning labels released last month by the Food and Drug Administration already appear to be having one desired effect: an increase in "quit smoking" queries to the national 1-800-QUIT-NOW smoking cessation line, the Associated Press reported Saturday.

The new labels aren’t even on cigarette packages yet — the labels will be implemented next year.

July 5, 2011

Sagent has received approval from the Food and Drug Administration for its antibacterial drug.

SCHAUMBURG, Ill. — Sagent has received approval from the Food and Drug Administration for its antibacterial drug.

The drug maker said that the FDA approved polymyxin B for injection USP. Sagent said that polymyxin B sulfate is used to treat infections of the urinary tract, meninges and bloodstream caused by susceptible strains of Pseudomonas aeruginosa.

The drug was developed in partnership with Strides Arcolab. Under the collaboration, Strides develops and supplies injectable products that Sagent will market in the United States.

July 5, 2011

Sam's Club is highlighting health-and-wellness issues through its latest campaign, and has pledged to donate up to $2 million to four nonprofits.

BENTONVILLE, Ark. — Sam's Club is highlighting health-and-wellness issues through its latest campaign, and has pledged to donate up to $2 million to four nonprofits.

The retailer's 2011 Giving Made Simple campaign allows Sam's Club members and associates to direct a portion of the company's donations to four health-related nonprofit organizations: Alliance for a Healthier Generation, OASIS, Sesame Street and The Y.

July 5, 2011

Shire has filed patent infringement suits against two generic drug makers relating to its attention deficit hyperactivity disorder treatment.

DUBLIN — Shire has filed patent infringement suits against two generic drug makers relating to its attention deficit hyperactivity disorder treatment.

Shire said it has filed lawsuits in the U.S. District Court for the District of New Jersey against Amneal Pharmaceuticals and Sandoz. Amneal and Sandoz recently filed abbreviated new drug applications with the Food and Drug Administration to market generic Vyvanse (lisdexamfetamine), an ADHD drug.

July 5, 2011

St. Joseph Aspirin has returned to store shelves with a series of product, packaging and retail enhancements, Ilex Consumer Products Group announced last month.

BALTIMORE — St. Joseph Aspirin has returned to store shelves with a series of product, packaging and retail enhancements, Ilex Consumer Products Group announced last month.

The new packaging will target baby boomers on a low-dose aspirin regimen, as recommended by doctors, to help lower the risk of heart attack and stroke. The new packaging copy calls out the need for the consumer to engage in an “Aspirin Regimen.”

July 5, 2011

The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating deep vein thrombosis in patients undergoing knee or hip replacement surgery, a J&J subsidiary said Friday.

RARITAN, N.J. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating deep vein thrombosis in patients undergoing knee or hip replacement surgery, a J&J subsidiary said Friday.

Janssen Pharmaceuticals announced the approval of Xarelto (rivaroxaban) tablets as a once-daily oral anticoagulant for DVT, a condition that could lead to pulmonary embolism.

June 30, 2011

Just about everybody seems satisfied with Diplomat Specialty Pharmacy’s services, according to the company’s 2011 patient satisfaction survey.

FLINT, Mich. — Just about everybody seems satisfied with Diplomat Specialty Pharmacy’s services, according to the company’s 2011 patient satisfaction survey.

Diplomat mailed the survey to 1,545 customers in May, of whom 463 responded. Of those respondents, 90% said Diplomat exceeded their expectations; 98% said it met their expectations; and 99% said they were satisfied overall with the specialty pharmacy provider.

Diplomat president and CEO Phil Hagerman said the results affirmed the provider’s patient-focused model.

June 30, 2011

Impax Labs has agreed not to market a generic version of a drug designed to reduce blood sugar and cholesterol in tablet form until 2015.

HAYWARD, Calif. — Impax Labs has agreed not to market a generic version of a drug designed to reduce blood sugar and cholesterol in tablet form until 2015.